Rising stars of DPLD survival: FVC and exercise desaturation (a single-center study)

Background/aim: Diffuse parenchymal lung diseases (DPLDs) comprise a broad, heterogeneous group of diseases with commonfunctional characteristics and a common final pathway, usually leading to irreversible fibrosis. We investigated the effects of thephysiological and functional parameters and of pulmonary hypertension (PH) on survival in DPLDs.Materials and methods: The study included 158 patients with DPLDs. Patient data were examined retrospectively, and survival statuswas obtained through phone calls.Results: Patients were divided into five groups according to their diagnosis: idiopathic pulmonary fibrosis (IPF), non-IPF idiopathicinterstitial pneumonias, connective tissue diseases, sarcoidosis, and other DPLDs. Median survival was 42.9 months. The significantnegative effects of older age, presence of delta saturation (DeltaSat; difference between oxygen saturation at rest and after the 6-minwalking test), 6-min walking distance (

PDF

___

Cosgrove GP, Schwarz MI. Approach to the evaluation and diagnosis of interstitial lung disease. In: Schwarz MI, King TE, editors. Interstitial Lung Disease. 5th ed. Shelton, CT, USA: People’s Medical Clearing House; 2011. pp. 3-25.
Antin-Ozerkis D. Interstitial lung disease: a clinical overview and general approach. In: Fishman AP, editors. Fishman’s Pulmonary Diseases and Disorders. 5th ed. New York, NY, USA: McGraw-Hill; 2015. pp. 810-822.
American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. General principles and recommendations. Am J Crit Care Med 2002; 165: 277-304.
Leslie KO, Trahan S, Gruden J. Pulmonary pathology of the rheumatic diseases. Semin Respir Crit Care Med 2007; 28: 369- 378.
King TE. Connective tissue disease. In: Schwarz MI, King TE editors. Interstitial Lung Disease. 3rd ed. London, Canada: BC Decker; 1998. pp. 451-505
Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF, du Bois R, Eklund A, Kitaichi M, Lynch J, Rizzato G et al. ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16: 73-149.
O’Donnell DE, Fitzpatrick MF. Physiology of interstitial lung disease. In: Schwarz MI, King TE Jr, editors. Interstitial Lung Disease. 4th ed. London, Canada: BC Decker; 2003. pp. 54-74.
ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six minute walk test. Am J Respir Crit Care Med 2002; 166: 111-117.
du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Sahn SA, Szwarcberg J et al. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med 2011; 183: 1231-1237.
Eaton T, Young P, Milne D, Wells AU. Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005; 171: 1150-1157.
Blanco I, Villaquiran C, Valera JL, Molina-Molina M, Xaubet A, Rodriguez-Roisin R, Barbera JA, Roca J. Peak oxygen uptake during the six-minute walk test in diffuse interstitial lung disease and pulmonary hypertension. Arch Bronconeumol 2010; 46: 122-128.
Lama VN, Flaherty KR, Toews GB, Colby TV, Travis WD, Long Q, Murray S, Kazerooni EA, Gross BH, Lynch JP 3rd et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168: 1084-1090.
Flaherty KR, Andrei AC, Murray S, Fraley C, Colby TV, Travis WD, Lama V, Kazerooni EA, Gross BH, Toews GB et al. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med 2006; 174: 803-809.
Lettieri CJ, Nathan SD, Browning RF, Barnett SD, Ahmad S, Shorr AF. The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis. Respir Med 2006; 100: 1734- 1741.
Maloney JP. Advances in the treatment of secondary pulmonary hypertension. Curr Opin Pulm Med 2003; 9: 139-143.
Shapiro S. Management of pulmonary hypertension resulting from interstitial lung disease. Curr Opin Pulm Med 2003; 9: 426-430.
Strange C, Highland KB. Pulmonary hypertension in interstitial lung disease. Curr Opin Pulm Med 2005; 11: 452-455.
Behr J, Ryu JH. Pulmonary hypertension in interstitial lung disease. Eur Respir J 2008; 31: 1357-1367.
du Bois R, Albera C, Bradford W, Costabel U, Hormel P, King T Jr, Noble P, Szwarcberg J, Thomeer M, Valeyre D et al. Predictors of mortality in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179: A1114.
Hanson D, Winterbauer RH, Kirtland SH, Wu R. Changes in pulmonary function test results after 1 year therapy as predictors of survival in patients with idiopathic pulmonary fibrosis. Chest 1995; 108: 305-310.
Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH, Colby TV, Travis WD, Flint A, Toews GB, Lynch JP 3rd et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168: 543-548.
Latsi PI, du Bois RM, Nicholson AG, Colby TV, Bisirtzoglou D, Nikolakopoulou A, Veeraraghavan S, Hansell DM, Wells AU. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003; 168: 531-537.
Jegal Y, Kim DS, Shim TS, Lim CM, Do Lee S, Koh Y, Kim WS, Kim WD, Lee JS, Travis WD et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005; 171: 639-644.
Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK, Hirani N, Hubbard R, Lake F, Millar AB et al. Interstitial Lung Disease Guideline: The British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008; 63 (Suppl. 5): 1-58.
Zisman DA, Ross DJ, Belperio JA, Saggar R, Lynch JP 3rd, Ardehali A, Karlamangla AS. Prediction of pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Med 2007; 101: 2153-2159.
Steen VD, Graham G, Conte C, Owens G, Medsger TA Jr. Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 1992; 35: 765-770.
Agusti AG, Roca J, Gea J, Wagner PD, Xaubet A, RodriguezRoisin R. Mechanisms of gas-exchange impairment in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1991; 143: 219-225.
Hallstrand TS, Boitano LJ, Johnson WC, Spado CA, Hyes JG, Raghu G. The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis. Eur Respir J 2005; 25: 96-103.
Bourbonnais JM, Samavati L. Clinical predictors of pulmonary hypertension in sarcoidosis. Eur Respir J 2008; 32: 296-302.
Villalba WO, Sampaio-Barros PD, Pereira MC, Cerqueira EMFB, Leme CA, Marques-Neto JF, Paschoal IA. Six minute walk test for evaluation of pulmonary disease severity in scleroderma patients. Chest 2007; 131: 217-222.
Cote CG, Casanova C, Marin JM, Lopez MV, Pinto-Plata V, de Oca MM, Dordelly LJ, Nekach H, Celli BR. Validation and comparison of reference equations fort the 6-min walk distance test. Eur Respir J 2008; 31: 571-578.
Lettieri C, Nathan SD, Barnett S, Ahmad S, Shorr A. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006; 129: 746-752.
Shorr A, Wainright JL, Cors CS, Lettieri C, Nathan SD. Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplantation. Eur Respir J 2007; 30: 715-721.
Shorr A, Davies DB, Nathan SD. Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest 2003; 124: 922-928.
Cottin V, Nunes H, Brillet PY, Delaval P, Devouassoux G, TillieLeblond I, Israel-Biet D, Court-Fortune I, Valeyre D, Cordier JF et al. Combined pulmonary fibrosis and emphysema: a distinct under recognised entity. Eur Respir J 2005; 26: 586-593.
Nathan SD, Shlobin OA, Ahmad S, Urbanek S, Barnett SD. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest 2007; 131: 657-663.
Collard HR, King TE, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168: 538-542.
Gay SE, Kazerooni EA, Toews GB, Lynch JP 3rd, Gross BH, Cascade PN, Spizarny DL, Flint A, Schork MA, Whyte RI et al. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med 1998; 157: 1063-1072.
Nadraus H, Pellikka P, Krowka MJ, Swanson KL, Chaowalit N, Decker PA, Ryu JH. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 2005; 128: 2393-2399.
Perez A, Rogers RM, Dauber JH. The prognosis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2003; 29 (Suppl. 3): 19-26.
Kishaba T, Nagano H, Nei Y, Yamashiro S. Body mass index— percent forced vital capacity—respiratory hospitalization: new staging for idiopathic pulmonary fibrosis patients. J Thorac Dis 2016; 8: 3596-3604.
Richards TJ, Kaminski N, Baribaud F, Flavin S, Brodmerkelet C, Horowitz D, Li K, Choi J, Vuga LJ, Lindell KO et al. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 185: 67-76.
Hamai K, Iwamoto H, Ishikawa N, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Ohshimo S, Fujitaka K, Hamada H et al. Comparative study of circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as disease markers of idiopathic pulmonary fibrosis. Dis Markers 2016; 2016: 4759040.